Javascript must be enabled to continue!
The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma
View through CrossRef
AbstractEarly detection improves survival and increases curative probability in hepatocellular carcinoma (HCC). Peripheral blood mononuclear cells (PBMCs) can provide an inexpensive, less-invasive and highly accurate method. The objective of this study is to find the potential marker for HCC screening, utilizing gene expression of the PBMCs. Data from the NCBI GEO database of gene expression in HCC patients and healthy donor's PBMCs was collected. As a result, GSE 49515 and GSE 58208 were found. Using both, a statistical significance test was conducted in each gene expression of each data set which resulted in 187 genes. We randomized three selected genes (FLNA, CAP1, and CLU) from the significant p-value group (p-values < 0.001). Then, a total of 76 healthy donors, 153 HCC, 20 hepatic fibrosis, 20 non-alcoholic fatty liver were collected. Quantitative RT-PCR (qRT-PCR) was performed in cDNA from all blood samples from the qRT-PCR, The Cycle threshold (Ct) value of FLNA, CLU, CAP1 of HCC group (28.47 ± 4.43, 28.01 ± 3.75, 29.64 ± 3.90) were lower than healthy group (34.23 ± 3.54, 32.90 ± 4.15, 32.18 ± 5.02) (p-values < 0.0001). The accuracy, sensitivity and specificity of these genes as a screening tool were: FLNA (80.8%, 88.0%, 65.8%), CLU (63.4%, 93.3%, 31.3%), CAP1 (67.2%, 83.3%, 39.1%). The tests were performed in two and three gene combinations. Results demonstrated high accuracy of 86.2%, sensitivity of 85% and specificity of 88.4% in the FLNA and CLU combination. Furthermore, after analyzed using hepatic fibrosis and non-alcoholic fatty liver as a control, the FLNA and CLU combination is shown to have accuracy of 76.9%, sensitivity of 77.6% and specificity of 75%. Also, we founded that our gene combination performs better than the current gold standard for HCC screening. We concluded that FLNA and CLU combination have high potential for being HCC novel markers. Combined with current tumor markers, further research of the gene’s expression might help identify more potential markers and improve diagnosis methods.
Springer Science and Business Media LLC
Title: The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma
Description:
AbstractEarly detection improves survival and increases curative probability in hepatocellular carcinoma (HCC).
Peripheral blood mononuclear cells (PBMCs) can provide an inexpensive, less-invasive and highly accurate method.
The objective of this study is to find the potential marker for HCC screening, utilizing gene expression of the PBMCs.
Data from the NCBI GEO database of gene expression in HCC patients and healthy donor's PBMCs was collected.
As a result, GSE 49515 and GSE 58208 were found.
Using both, a statistical significance test was conducted in each gene expression of each data set which resulted in 187 genes.
We randomized three selected genes (FLNA, CAP1, and CLU) from the significant p-value group (p-values < 0.
001).
Then, a total of 76 healthy donors, 153 HCC, 20 hepatic fibrosis, 20 non-alcoholic fatty liver were collected.
Quantitative RT-PCR (qRT-PCR) was performed in cDNA from all blood samples from the qRT-PCR, The Cycle threshold (Ct) value of FLNA, CLU, CAP1 of HCC group (28.
47 ± 4.
43, 28.
01 ± 3.
75, 29.
64 ± 3.
90) were lower than healthy group (34.
23 ± 3.
54, 32.
90 ± 4.
15, 32.
18 ± 5.
02) (p-values < 0.
0001).
The accuracy, sensitivity and specificity of these genes as a screening tool were: FLNA (80.
8%, 88.
0%, 65.
8%), CLU (63.
4%, 93.
3%, 31.
3%), CAP1 (67.
2%, 83.
3%, 39.
1%).
The tests were performed in two and three gene combinations.
Results demonstrated high accuracy of 86.
2%, sensitivity of 85% and specificity of 88.
4% in the FLNA and CLU combination.
Furthermore, after analyzed using hepatic fibrosis and non-alcoholic fatty liver as a control, the FLNA and CLU combination is shown to have accuracy of 76.
9%, sensitivity of 77.
6% and specificity of 75%.
Also, we founded that our gene combination performs better than the current gold standard for HCC screening.
We concluded that FLNA and CLU combination have high potential for being HCC novel markers.
Combined with current tumor markers, further research of the gene’s expression might help identify more potential markers and improve diagnosis methods.
Related Results
The Expression of FLNA and CLU in PBMCs As A Novel Screening Marker for Hepatocellular Carcinoma.
The Expression of FLNA and CLU in PBMCs As A Novel Screening Marker for Hepatocellular Carcinoma.
Abstract
Early detection improves survival and increases curative probability in hepatocellular carcinoma (HCC). Peripheral blood mononuclear cells (PBMCs) can provide an i...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Insight into the impact of diabetes mellitus on the increased risk of hepatocellular carcinoma: mini-review
Insight into the impact of diabetes mellitus on the increased risk of hepatocellular carcinoma: mini-review
AbstractHepatocellular carcinoma is a multifactorial disease which is associated with a background of many causal risk factors. Diabetes mellitus however is one of the most common ...
Long interval between HCV infection and development of hepatocellular carcinoma
Long interval between HCV infection and development of hepatocellular carcinoma
Abstract: A high prevalence of HCV infection has been reported in patients with hepatocellular carcinoma. The progression from acute transfusion‐associated hepatitis to hepatic ci...
Systematic pan-cancer analyses of the potential function of the Golgi scaffold protein PAQR3
Systematic pan-cancer analyses of the potential function of the Golgi scaffold protein PAQR3
AbstractProgesterone and AdipoQ Receptor 3 (PAQR3) is a member of the AdipoQ receptor. Our previous studies have found that PAQR3 plays a role as a candidate inhibitor in cardiac a...
Identification of a Novel Biomarker Based Peripheral Blood Mononuclear Cells Gene Expression for Diagnosis and Prognosis of Hepatocellular Carcinoma.
Identification of a Novel Biomarker Based Peripheral Blood Mononuclear Cells Gene Expression for Diagnosis and Prognosis of Hepatocellular Carcinoma.
Abstract
Novel and sensitive biomarkers is highly required for early detection and predicting prognosis of hepatocellular carcinoma (HCC). Here, we investigated transcripti...
Identification of BHLHE40 expression in peripheral blood mononuclear cells as a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma
Identification of BHLHE40 expression in peripheral blood mononuclear cells as a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma
AbstractNovel and sensitive biomarkers is highly required for early detection and predicting prognosis of hepatocellular carcinoma (HCC). Here, we investigated transcription profil...
Carcinoma ex Pleomorphic Adenoma: A Case Series and Literature Review
Carcinoma ex Pleomorphic Adenoma: A Case Series and Literature Review
Abstract
Introduction
Carcinoma ex pleomorphic adenoma (CXPA) is a rare malignant salivary gland tumor that can lead to severe complications and carries a risk of distant metastasi...

